« Back
Home /
Afuresertib (hydrochloride)

Afuresertib (hydrochloride)

Item no.	HY-15727A-5mg
Manufacturer	MedChem Express
CASRN	1047645-82-8
Amount	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 50 mg 5 mg
Category	Oncology Neuroscience Metabolism Diabetes Aging & Neurological Disorders Inhibitors & Compound Libraries Small Molecules By Organ Breast Cancer Uterine, Ovarian & Cervical Cancer
Type	Inhibitors
Specific against	other
Purity	99.95
Citations	[1]Yamaji M, et al. Novel ATP-competitive Akt inhibitor Afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6(11):2646-2659.\|[2] Dumble M, et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS One. 2014 Jun 30;9(6):e100880 Patent. US20230147129A1.\|Cancers (Basel). 2022 May 19;14(10):2493.\|Cell Syst. 2018 Apr 25;6(4):424-443.e7.\|Cell. 2024 Feb 1;187(3):624-641.e23.\|Cold Spring Harb Mol Case Stud. 2022 Jan 10;8(1):a006140.\|Genes Dis. 2021 Aug 17;9(2):562-575.\|Int J Cancer. 2020 Apr 1;146(7):1963-1978. \|J Biol Chem. 2024 Jan 9:105641.\|J Cell Biochem. 2024 Jun 11.\|J Physiol. 2017 Jul 1;595(13):4207-4225.\|Methods Mol Biol. 2018;1711:351-398.\|Molecules. 2019 Apr 1;24(7):1260.\|Research Square Print. October 27th, 2022.\|Sci Transl Med. 2021 Jan 27;13(578):eaba7308.\|Theranostics. 2019 Jan 30;9(4):1096-1114.
Smiles	O=C(C1=CC(C2=C(Cl)C=NN2C)=C(Cl)S1)N[C@@H](CC3=CC=CC(F)=C3)CN.[H]Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	GSK2110183 (hydrochloride),LAE002 (hydrochloride)
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Akt; PKC; ROCK
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, protect from light, stored under nitrogen)
Molecular Weight	463.78
Product Description	Afuresertib hydrochloride (GSK 2110183 hydrochloride) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with Kis of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively[1][2].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 250 mg/mL (ultrasonic)
Manufacturer - Pathway	Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad
Isoform	Akt1; Akt2; Akt3; PKCβ; PKCη; PKCθ; ROCK
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-15727A-5mg-safety-datasheet.pdf